In DepthInfectious Diseases

Successful Ebola treatments promise to tame outbreak

See allHide authors and affiliations

Science  16 Aug 2019:
Vol. 365, Issue 6454, pp. 628-629
DOI: 10.1126/science.365.6454.628

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

In November 2018, a randomized clinical trial was launched in the midst of an Ebola outbreak in the eastern Democratic Republic of the Congo (DRC). In the trial, conducted at four sites in the country, patients were treated with one of three antibody therapies or an antiviral drug called remdesivir. On 9 August, after reviewing preliminary data on 499 patients, an independent data and safety monitoring board recommended that the trial be stopped. Two of the treatments had shown strong signs of being able to save patients' lives. Now, anyone seeking treatment with Ebola will be offered one of the two drugs, the antibody mAb114 or the antibody cocktail REGN-EB3. Scientists hope this will help bring the outbreak under control, which has grown to be the deadliest in the DRC's history.

View Full Text